Login / Signup

Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine.

Soohyun ChoByung-Kun Kim
Published in: Current pain and headache reports (2024)
Real-world studies involving patients with migraine have reported consistent findings of worsened headache frequency and quality of life after the discontinuation of CGRP monoclonal antibodies (CGRP mAbs). Although many patients maintain improvements for up to 4 months after discontinuation compared to baseline (before starting CGRP mAbs), no studies have evaluated the effects of stopping treatment for > 5 months, which is the five-half-life of CGRP mAbs. Several studies have suggested that patients treated with CGRP receptor mAbs experience more rapid deterioration than those treated with CGRP ligand mAbs after discontinuing CGRP mAbs. The results of real-world studies suggest that for many patients with migraine, the benefits of CGRP mAbs diminish months after discontinuation. Therefore, anti-CGRP therapies may not be considered disease-modifying. However, the comprehensive assessment of the disease-modifying potential of these drugs requires studies with extended treatment and cessation durations.
Keyphrases
  • case control
  • end stage renal disease
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • ejection fraction
  • risk assessment
  • climate change
  • combination therapy
  • human health